OTCPK:VXRTBiotechs
Vaxart (VXRT) Revenue Surge To US$72.4 Million Tests Bearish Decline Narrative
Vaxart (VXRT) has reported another loss making quarter, with Q3 FY 2025 revenue of about US$72.4 million and a basic EPS loss of US$0.04, alongside trailing twelve month revenue of roughly US$148.2 million and a basic EPS loss of US$0.22. Over recent periods, the company has seen quarterly revenue move from US$4.9 million in Q3 FY 2024 to US$15.2 million in Q4 FY 2024, then to US$20.9 million in Q1 FY 2025 and US$39.7 million in Q2 FY 2025. Basic EPS losses have ranged from US$0.09 in Q2 FY...